A new era in the treatment of multiple sclerosis

Simon Broadley, Michael Barnett, Mike Boggild, Bruce Brew, Helmut Butzkueven, Robert Heard, Suzanne Hodgkinson, Allan Kermode, Jeannette Lechner-Scott, Richard Macdonell, Mark Marriott, Devorah. Mason, John Parratt, Stephen Reddel, Cameron Shaw, Mark Slee, Judith Sples, Bruce Taylor, William Carroll, Trevor KillpatrickJohn King, Pamela McCombe, John Pollard, Ernest Willoughby

    Research output: Contribution to journalArticlepeer-review

    8 Citations (Scopus)

    Abstract

    Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. The importance of early treatment in minimising long-term disability is increasingly recognised. Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.

    Original languageEnglish
    Pages (from-to)139-141
    Number of pages3
    JournalMedical Journal of Australia
    Volume203
    Issue number3
    DOIs
    Publication statusPublished - 3 Aug 2015

    Fingerprint Dive into the research topics of 'A new era in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

    Cite this